Cargando…

Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients

BACKGROUND: Aim of this study was to evaluate the efficacy and the safety of switching from branded to generic antiretrovirals in patients with HIV-RNA <50 copies/mL. METHODS: Matched-cohort study of patients followed at a single clinical center. Since September 2014, all patients with HIV-RNA &l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gianotti, Nicola, Poli, Andrea, Galli, Laura, Franzin, Michela, Tadini, Patrizia, Galizzi, Nadia, Carbone, Alessia, Merli, Marco, Muccini, Camilla, Oltolini, Chiara, Andolina, Andrea, Spagnuolo, Vincenzo, Lazzarin, Adriano, Castagna, Antonella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538668/ https://www.ncbi.nlm.nih.gov/pubmed/28763473 http://dx.doi.org/10.1371/journal.pone.0182007

Ejemplares similares

Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Achieving virological control in pan-resistant HIV-1 infection: A case series
por: Canetti, Diana, et al.
Publicado: (2022)

Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy
por: Gianotti, Nicola, et al.
Publicado: (2015)

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2019)

Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients
por: Spagnuolo, Vincenzo, et al.
Publicado: (2017)

Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression
por: Carbone, Alessia, et al.
Publicado: (2014)

Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir
por: Gianotti, Nicola, et al.
Publicado: (2016)

Increasing trend of transmitted integrase inhibitor resistance in a cohort of antiretroviral therapy-naive people living with HIV
por: Muccini, Camilla, et al.
Publicado: (2023)

Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load
por: Galizzi, Nadia, et al.
Publicado: (2018)

Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting
por: Colombo, Giorgio L, et al.
Publicado: (2013)

Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors
por: Ripa, Marco, et al.
Publicado: (2021)

Predictors of lack of serological response to syphilis treatment in HIV-infected subjects
por: Spagnuolo, Vincenzo, et al.
Publicado: (2014)

Increasing incidence and prevalence of metabolic syndrome in people living with HIV during the COVID-19 pandemic
por: Papaioannu Borjesson, Rebecka, et al.
Publicado: (2023)

Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV
por: Spagnuolo, Vincenzo, et al.
Publicado: (2018)

Association between low levels of HIV-1 DNA and HLA class I molecules in chronic HIV-1 infection
por: Muccini, Camilla, et al.
Publicado: (2022)

Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice
por: Ranzenigo, Martina, et al.
Publicado: (2022)

Brand and generic medications: Are they interchangeable?
por: Al-Jazairi, Abdulrazaq S., et al.
Publicado: (2008)

Prescription writing: Generic or brand?
por: Andrade, Chittaranjan, et al.
Publicado: (2017)

Brand Name Versus Generic?
por: Aungaroon, Gewalin
Publicado: (2023)

Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study
por: Desai, Rishi J, et al.
Publicado: (2018)

Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy
por: Muccini, Camilla, et al.
Publicado: (2022)

Generic versus brand-name drugs used in cardiovascular diseases
por: Manzoli, Lamberto, et al.
Publicado: (2015)

Antiretroviral generics
por: Andrieu, Véronique
Publicado: (2012)

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Safety and efficacy of generic drugs with respect to brand formulation
por: Gallelli, Luca, et al.
Publicado: (2013)

Evaluation of Physical Properties of Generic and Branded Travoprost Formulations
por: Wadhwani, Meenakshi, et al.
Publicado: (2016)

Cyclosporine: A Commentary on Brand versus Generic Formulation Exchange
por: Singh, A. K., et al.
Publicado: (2011)

A critical review of brand and generic alendronate for the treatment of osteoporosis
por: Brown, Jacques P, et al.
Publicado: (2013)

Assessment of the equivalence of a generic to a branded femoral stem
por: Hothi, H., et al.
Publicado: (2017)

Potential Clinical and Economic Impact of Switching Branded Medications to Generics
por: Straka, Robert J., et al.
Publicado: (2017)

Bioequivalence of generic and branded amoxicillin capsules in healthy human volunteers
por: Pathak, Priyanka, et al.
Publicado: (2017)

HPLC-Based Analysis of Impurities in Sapropterin Branded and Generic Tablets
por: Scudellaro, Emanuela, et al.
Publicado: (2020)

Generics versus brand-named drugs for glaucoma: the debate continues
por: Bhartiya, Shibal, et al.
Publicado: (2020)

Pharmacist Intervention in Safe and Effective Conversion of Brand to Generic Drugs
por: Summers, Kent H.
Publicado: (2005)

Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: Results of a prospective Italian study
por: Morsica, Giulia, et al.
Publicado: (2017)

A comparative evaluation of price and quality of some branded versus branded–generic medicines of the same manufacturer in India
por: Singal, G.L., et al.
Publicado: (2011)

From generic scheme to brand-generic scheme: Have new policy influenced the efficiency of Iranian pharmaceutical companies?
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2014)

The concept of: Generic drugs and patented drugs vs. brand name drugs and non-proprietary (generic) name drugs
por: Thakkar, Karan B., et al.
Publicado: (2013)

Retrospective Database Analysis to Explore Patterns and Economic Burden of Switchback to Brand After Generic or Authorized Generic Utilization
por: Alderfer, Justine, et al.
Publicado: (2022)

Analyzing generic and branded substitution patterns in the Netherlands using prescription data
por: Pechlivanoglou, Petros, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_3tg5n7qol65sqg940akngk7hee